- Home
- RGT vs MAIA Comparison
RGT vs MAIA Comparison
Compare RGT & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RGT | MAIA |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | United States |
| Employees | N/A | 13 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.0M | 89.7M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | RGT | MAIA |
|---|---|---|
| Price | $13.71 | $1.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 21.4K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | N/A | ★ 29.53 |
| EPS | ★ 0.92 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.04 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.00 | $0.87 |
| 52 Week High | $14.99 | $3.19 |
Technical Indicators
Market Signals| Indicator | RGT | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 39.25 | 38.48 |
| Support Level | $12.50 | $1.20 |
| Resistance Level | $14.95 | $1.66 |
| Average True Range (ATR) | 0.22 | 0.16 |
| MACD | -0.09 | -0.05 |
| Stochastic Oscillator | 14.31 | 13.43 |
Price Performance
Historical ComparisonAbout RGT Royce Global Value Trust Inc.
Royce Global Value Trust Inc is a diversified closed-end investment company. The fund spreads its investments across diversified sectors such as information technology, consumer discretionary, health care, materials, consumer staples, and energy. Geographically, it has presence in the region of the United Kingdom, Japan, the United States, Canada, France, Hong Kong, and Germany.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.